Abstract
Increasingly, government policies directed towards limiting pharmaceutical prices have emphasized value-based criteria. This regulatory approach is most clearly formalized in the United Kingdom where the National Institute for Health and Clinical Excellence (NICE) was created within the British National Health Service (NHS), whose function is to apply cost-effectiveness analysis to new drugs. In contrast to Britain, there is no formal regulatory mechanism assuring cost-effectiveness in the United States. Instead, questions of cost effectiveness are left to market processes. In this paper, we examine the pricing implications of these alternate regimes. From our empirical analysis, we conclude that value-based pricing is enforced by both regulatory and market processes, and with similar outcomes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Department of Health and the Association of the British Pharmaceutical Industry. (2013). The pharmaceutical price regulation scheme 2014, December 2013, Gov.UK.
Drummond, M., et al. (1987). Methods for economic evaluation of health care programmes. New York: Oxford University Press.
Ekelund, M., & Persson, B. (2003). Pharmaceutical pricing in a regulated market. Review of Economics and Statistics, 85, 298–306.
Faden, R. R., & Chalkidou, K. (2011). Determining the value of drugs: The evolving British experience. New England Journal of Medicine, 364, 1289–1291.
George, E. (2010). Associate Director of NICE, Interview, London, April 2010.
Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost effectiveness in health and medicine. New York: Oxford University Press.
IMS Institute for Healthcare Informatics. (2015). Medicines use and spending shifts. Parsippany, NJ.
Jena, A. B., & Philipson, T. J. (2013). Endogenous cost-effectiveness analysis and health care technology adoption. Journal of Health Economics, 32, 172–180.
Lu, Z. J., & Comanor, W. S. (1998). Strategic pricing of new pharmaceuticals. Review of Economics and Statistics, 80, 108–118.
Nolte, E., & Corbett, J. (2014). International variation in drug usage. London: RAND Europe.
O’Neill, P., & Sussex, J. (2014). International comparison of medicines usage: Quantitative analysis. London: Office of Health Economics.
Rawlins, M. D. (2013). NICE: Moving onward. New England Journal of Medicine, 369, 3–5.
Reekie, W. D. (1978). Price and quality competition in the United States drug industry. Journal of Industrial Economics, 26, 223–237.
Richards, M. (2010). Extent and causes of international variations in drug use. A report for the Secretary of State for Health, UK, July 2010.
Scherer, F. M. (2000). The pharmaceutical industry. In A. J. Culyer & J. P. Newhouse (Eds.), Handbook of health economics (pp. 1298–1336). Amsterdam: Elsevier.
Scherer, F. M. (2010). Chapter 12: Pharmaceutical innovation. In B. H. Hall & N. Rosenberg (Eds.), Economics of innovation: Handbook on the economics of innovation (Vol. 1, pp. 539–574). Amsterdam: Elsevier.
Schweitzer, S. O. (2007). Pharmaceutical economics and policy (2nd ed.). New York: Oxford University Press.
US Center for Health Statistics. (2014). Health United States. Washington: Department of Health and Human Services.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Comanor, W.S., Schweitzer, S.O., Riddle, J.M. et al. Value Based Pricing of Pharmaceuticals in the US and UK: Does Centralized Cost Effectiveness Analysis Matter?. Rev Ind Organ 52, 589–602 (2018). https://doi.org/10.1007/s11151-018-9616-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11151-018-9616-1